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Summary Secretion of ectopic adrenocorticotropic hormone (ACTH) with con-
sequently Cushing’s syndrome is a rare paraneoplastic phenomenon. It has been
described in a variety of malignancies, like bronchial carcinoids, small-cell lung
carcinoma, thymoma, pancreatic carcinoma and other. In many cases of suspected
ectopic ACTH secretion, it is difﬁcult to histologically or cytochemically conﬁrm the
diagnosis. We present a 63-year-old woman with a recurrent poorly differentiated
squamous cell lung carcinoma with clinical and biochemical features consistent with
ectopic Cushing’s syndrome. Immunocytochemical staining conﬁrmed the secretion
of ACTH by tumour cells.
© 2005 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
‘‘The name of Harvey Cushing (1869—1939) was
immortalized in the history of medicine, by his dis-
covery, in 1912, of Cushing’s disease, an endocrine
syndrome caused by a malfunction of the pituitary
gland. This discovery was described in detail in: The
Pituitary Body and its Disorders [1].’’
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Cushing’s syndrome is characterized by truncal
obesity, a ‘buffalo hump’ and/or ‘moon face’, pur-
plish abdominal striae, ecchymoses and proximal
myopathy, accompanied by non-speciﬁc symptoms
like edema, hypertension, fatigability and weak-
ness, hirsutism, hyperpigmentation and diabetes.
The syndrome can be ACTH-independent due to
autonomous glucocorticoid-secreting adrenocorti-
cal adenomas or carcinomas. However, in most
cases Cushing’s syndrome is ACTH-dependent. The
aetiology is bilateral adrenal hyperplasia due to
hypersecretion of pituitary ACTH or ectopic produc-
tion of ACTH by a non-pituitary cause like malig-
nancy, respectively called Cushing’s disease and
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Cushing’s syndrome. Numerous tumours have been
reported to secrete ACTH, like bronchial carci-
noids, thymoma, pancreatic malignancy and small-
cell lung carcinomas (SCLC).
We present a patient with a previous history of
non-small-cell lung carcinoma (NSCLC), typical fea-
tures consistent with Cushing’s syndrome and medi-
astinal lymphadenopathy on computerized tomog-
raphy (CT).
2. Case report
In March 2005, a 63-year-old woman presented in
our hospital with progressive dyspnea. She had a
history of previous poorly differentiated squamous
cell lung carcinoma of the lower right lobe in June
2001. For this, she had a lobectomy in another hos-
pital with pathological tumour-staging pT1N0M0.
After the operation she had gradually gained 50 kg
of weight, which she ascribed to cessation of smok-
ing. In January 2005, the general practitioner diag-
nosed her with hypertension and diabetes.
At presentation, physical ﬁndings showed a
plasma ACTH-level (223 ng/l, Ref. range 7—50)
and plasma renin activity level (6.70 ng/ml/h, Ref.
range 0.8—5.5). Serum cortisol failed to suppress
following 1mg dexamethasone overnight (09:00 h
cortisol 1.55mol/l, Ref. range <0.14). Magnetic
resonance imaging (MRI) did not reveal adenomas
of the pituitary gland, suggesting that our patient
had ectopic ACTH syndrome (EAS).
To identify the source of the ectopic ACTH-
production while considering her previous his-
tory of a lung carcinoma, a thoracic CT-scan was
made, which showed mediastinal lymphadenopa-
thy. On the abdominal CT-scan, there were no
signs of adrenal hyperplasia or adenoma. Subse-
quently bronchoscopy was performed which did
not reveal abnormalities. Curved linear endoscopic
ultrasound-guided ﬁne-needle aspiration (EUS-FNA)
was performed to biopsy the enlarged lymph nodes
and cytological examination demonstrated poorly
differentiated squamous cell carcinoma. Assuming
the prior resected tumour in the lower right lobe
to be the primary tumour, this lymph node can be
regarded as N3. Immuno-cytochemical staining of
this specimen was positive for the neuroendocrine
marker CD56 and for ACTH, suggesting paraneoplas-
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tCushingoid appearance, with a moon face, buffalo
hump and centripetal obesity. There were no signs
of hirsutism or hyperpigmentation, nor where there
abdominal striae or ecchymoses. There was pit-
ting edema of the legs and some tachypnea. Blood
pressure was elevated (RR 175/75mmHg). Her med-
ication included a potassium sparing diuretic com-
bined with a loop diuretic to control hypertension
and edema, a biguanide to control glucose-levels
and inhalation-corticosteroids.
Initial laboratory evaluation revealed a severe
hypokalemia (K+ 1.8mmol/l, Ref. range 3.5—5.0)
with normal sodium, magnesium and calcium-levels
and a normal renal function. Arterial blood gas
analysis revealed a metabolic alkalosis with hypox-
emia (pH 7.60; BE 17.1; HCO3− 41.1mmol/l (Ref.
range 22—29), pO2 53.6mmHg (7.15 kPa) and pCO2
40.0mmHg (5.33 kPa)).
She was treated with intravenous and oral
potassium chloride and supplemental oxygen. The
diuretics were temporarily discontinued, however
a potassium-sparing diuretic had to be re-started
because of increasing edema of the legs. Hyper-
tension was treated by an angiotensin I-blocker,
utilizing its potassium-sparing quality.
Further investigations revealed high 09:00 h
plasma cortisol (1.58mol/l, Ref. range 0.18—0.72)
with loss of diurnal variation (midnight plasma
cortisol 1.43mol/l, Ref. range <0.21). Urinary
free cortisol was also elevated (12.16mol/24 h,
Ref. range 0.03—0.28mol/24 h), and so were theic Cushing’s syndrome (Fig. 1).
The patient was treated with ketoconazole
400mg three times daily) and plasma cortisol
evels decreased, as did the potassium-suppletion
eeded. She developed bacteraemia with Staphy-
ococcus Aureus-species, originating from a con-
aminated intravenous catheter. After two weeks
f antibiotic treatment, induction-chemotherapy
or TxN3M0 NSCLC was administered (Vinorelbin
5mg/m2 and Cisplatin 80mg/m2). Ten days later,
he developed bilateral pulmonary embolisms for
hich low molecular weight heparin (LMWH) was
tarted. The patient deceased 18 days after onset of
hemotherapy. Post-mortem autopsy revealed mul-
iple bilateral pulmonary embolisms as direct cause
f death.
. Discussion
n ACTH-dependent Cushing’s syndrome 20—25% of
ases are caused by ectopic ACTH syndrome (EAS).
t is well known that several lung tumours like
ronchial carcinoids and small cell lung carcinoma
re associated with EAS in approximately 1—5% of
ases [2,3]. In recent literature, bronchial carci-
oids seem to be the predominant cause of EAS,
hile the incidence of SCLC associated with EAS
eems to decrease [9]. A possible explanation for
his might be the declining incidence of SCLC, apart
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Fig. 1 Microscopy. (A) Giemsa Stain (200×): EUS-FNA
reveals numerous neoplastic cells with anaplastic nuclei.
(B) Immunocytochemistry with CD56 (200×): decoration
of the neoplastic cells with CD56. (C) Immunocytochem-
istry with ACTH (1000×): some neoplastic cells express
ACTH.
from the fact that SCLC associated with Cushing’s
syndrome will be less reported due to the known
association.
A non-small cell lung carcinoma causing ACTH-
dependent Cushing’s syndrome has been seldom
reported. In 1975, Imura et al. [4] reported three
patients with adenocarcinoma of the lung, three
patients with undifferentiated lungcarcinoma and
one patient with a squamous cell carcinoma of
the lung, which were all accompanied by ectopic
ACTH secretion. However, these patients had no
clinical signs of Cushing’s syndrome. Since then,
only four case-reports of NSCLC associated with
EAS have been published [5—8]. In two of these
cases, the diagnosis EAS could not be conﬁrmed by
tumour cell staining for ACTH or ACTH-precursors
[7,8]. In the present case, however, the cytologi-
cal material obtained stains for ACTH. Revision of
the initial pathology specimens of 2001 showed no
ACTH-expression by tumour cells at that time. It is
known that tumour-relapses can show further de-
differentiation while developing neuro-endocrine
features such as ACTH-secretion. For squamous cell
carcinoma this is seldom seen.
All variables strongly support paraneoplastic
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pype of Cushing’s syndrome in this patient rather
han a pituitary one. The existence of a lung car-
inoma with positive immunocytochemical staining
or ACTH is the most important observation. Fur-
hermore, a severe hypokalemic alkalosis is com-
on in EAS and is found in 71—100% of cases
f ectopic ACTH secretion, but only in 10% of
ases of pituitary ACTH syndrome [9]. Serum ACTH-
evels were markedly elevated and levels above
00mol/l, as in our patient, are rare in pitu-
tary Cushing’s syndrome. To exclude other causes
f Cushing’s syndrome, MRI of the pituitary gland
as performed. Although no micro-adenoma was
bserved, it is reported that about 50% of pituitary
icro-adenomas cannot be detected by MRI [21].
nfortunately, obduction of the brain was not per-
itted by the relatives of the deceased. Inferior
etrosal sinus ACTH sampling may be important in
istinguishing between pituitary and ectopic ACTH-
roduction [10]. In our case however, this sam-
ling was not performed because delay in inhibiting
ortisol-production with ketoconazole would neg-
tively inﬂuence the primary outcome. Further-
ore, delay could be regarded unethical because
f the ﬁnding of ACTH-positive cells by cytochemi-
al staining.
The ultimate manner to control paraneoplastic
CTH syndrome is dependent on successful treat-
ent of the primary tumour. There are several
eports about the complications of chemotherapy in
atients with ectopic ACTH-production. The com-
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plications reported are mostly related to severe
infections and gastrointestinal bleeding or ulcer-
ation [10,11]. A small study of Dimopoulos et al.
[12] reported nine out of 11 patients with SCLC
and paraneoplastic Cushing’s syndrome to decease
within two weeks after onset of chemotherapy.
Shepherd et al. [11] found that ectopic ACTH-
production is associated with a low response to
chemotherapy, short survival and a high rate of
complication.
Ketoconazole is used in the treatment of Cush-
ing’s syndrome, as it primarily inhibits CYP11B1
(11--hydroxylase) but also CYP11A1 (desmolase,
cholesterol side-chain cleavage enzyme) in the
adrenals. 11--hydroxylase is the enzyme respon-
sible for the hydroxylation of 11-deoxycortisol
to cortisol while desmolase converts cholesterol
to ı-5-pregnenolone [13—15]. Only a few reports
about the usefulness of glucosteroid biosynthesis
inhibitors in ectopic ACTH syndrome are published,
and they report controversial results [16—20]. In
the study of Winquist et al., the conclusions were
that ketoconazole did not prolong survival, but it
did provide a palliative hormonal response in two
third of patients. In our patient, after administra-
of three cases and review of the literature. Postgrad Med J
2001;77(909):464—7.
[4] Imura H, Matsukura S, Yamamoto H, Hirata Y, Nakai Y.
Studies on ectopic ACTH- producing tumors. II. Clinical
and biochemical features of 30 cases. Cancer 1975;35(5):
1430—7.
[5] Myers EA, Hardman JM, Worsham GF, Eil C. Adenocarcinoma
of the lung causing ectopic adrenocorticotropic hormone
syndrome. Arch Intern Med 1982;142(7):1387—9.
[6] Schott R, Chaouat A, Tavernier M, Kessler R, Weitzenblum E.
Paraneoplastic hypercorticism associated with a bronchial
adenocarcinoma. Rev Mal Respir 1999;16(3):395—7.
[7] Boon ES, Leers MP, Tjwa MK. Ectopic Cushing’s syn-
drome in a patient with squamous cell carcinoma of the
lung due to CRF-like production. Monaldi Arch Chest Dis
1994;49(1):19—21.
[8] Yoh K, Kubota K, Nomura M, Niho S, Goto K, Ohmatsu H, et
al. Cushing’s syndrome associated with adenocarcinoma of
the lung. Intern Med 2003;42(9):831—3.
[9] Wajchenberg BL, Mendonca BB, Liberman B, Pereira
MA, Carneiro PC, Wakamatsu A, et al. Ectopic
adrenocorticotropic hormone syndrome. Endocr Rev
1994;15(6):752—87.
[10] Terzolo M, Reimondo G, Ali A, Bovio S, Daffara F, Paccotti P,
et al. Ectopic ACTH syndrome: molecular bases and clinical
heterogeneity. Ann Oncol 2001;12(Suppl 2):S83—7.
[11] Shepherd FA, Laskey J, Evans WK, Goss PE, Johansen E,
Khamsi F. Cushing’s syndrome associated with ectopic corti-
cotropin production and small-cell lung cancer. J Clin Oncol
1992;10(1):21—7.
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[tion of high doses of ketoconazole (400mg three
times daily), serum cortisol-levels and subsequently
hypokalemia were ﬁnally controlled.
The present patient died of recurrent bilateral
pulmonary thrombo-embolisms despite treatment
with LMWH. Both active malignancy and Cushing’s
syndrome are associated with a hypercoagulable
state because of an increase in plasma clotting fac-
tors like Factor VIII and von Willebrand factor com-
plex, and to an impairment of ﬁbrinolytic capacity
[22,23]. This could explain why our patient suffered
recurrent pulmonary embolisms despite adequate
anticoagulant treatment.
In conclusion, we believe this patient presented
with a Cushing’s syndrome paraneoplastic to a
poorly differentiated squamous cell carcinoma of
the lung. Although uncommon, ectopic Cushing’s
syndrome can also be found in NSCLC, and is asso-
ciated with a worse prognosis due to severe com-
plications.
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